2023
October 30, 2023
Precision Medicine Online
AnHeart Inks Deal With Nippon Kayaku to Bring Taletrectinib to Lung Cancer Patients in Japan
April 3, 2023
Clinical Trials Arena
AnHeart Therapeutics reports data from ROS1+ NSCLC therapy trial
March 31, 2023
OncLive
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
2022
December 15, 2022
Precision Oncology News
AnHeart Therapeutics Gets FDA Clearance to Study Safusidenib in IDH1-Mutant Glioma Patients
October 26, 2022
OncLive
Taletrectinib Shows Promising ORR and Tolerability in ROS1+ NSCLC
September 13, 2022
Pharmaceutical Business Review
AnHeart, NewG Lab receive orphan drug designation in Korea for NSCLC therapy
August 23, 2022
Endpoints New
August 5, 2022
Cancer Network
FDA Grants Breakthrough Therapy Designation to Taletrectinib for ROS1+ Non–Small Cell Lung Cancer
April 28, 2022
WSJ
March 21, 2022
MedCity News
Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy
January, 10-12, 2022
Biotech Showcase
2021
December 16, 2021
Bioworld
Anheart Therapeutics raises $61M in series B for precision oncology pipeline
December 14, 2021
Endpoints News
December 14, 2021
WSJ
AnHeart Takes Aim at Rare Mutation in Lung Cancer With $61 Million Financing
December 14, 2021
Biospace
With First Patients Dosed, AnHeart Snags $61 Million for Lung Cancer Hopeful
October 30, 2021
Targeted Oncology
Study of taletrectinib for ROS1 positive NSCLC Doses First Patient
October 26, 2021
Clinical Trials Arena
AnHeart Therapeutics begins dosing in Phase II lung cancer therapy trial
October 19, 2021
CURE Today
First Patient With NTRK Fusion-Positive Tumor Treated in Phase 2 Trial of Taletrectinib
September 28, 2021
OncLive
Taletrectinib Elicits Encouraging Responses in Crizotinib-Pretreated ROS1+ NSCLC
September 27, 2021
Cancer Network
Taletrectinib May Show Promise in ROS1+ Non–Small Cell Lung Cancer
September 27, 2021
European Pharmaceutical Review
Taletrectinib displays 90.5 percent objective response rate in NSCLC
